A nonblinded study was conducted to compare the pharmacokinetic properties of the selective serotonin reuptake inhibitor sertraline in 22 young (aged 18 to 45 years) and 22 elderly (> 65 years) volunteers, of whom half were male and half were female. In this study, sertraline was administered at a dosage of 200mg once daily (the maximum recommended daily dosage) for 21 days after upward dosage titration from 50 mg/day over a 9-day period. Thus, this study was designed to measure the effect of age and gender on the pharmacokinetic properties of sertraline at the maximum dosage recommended for clinical use.
The terminal elimination half-life (t½β) of sertraline was similar in young females, elderly males and elderly females (mean t½β ranged from 32.1 to 36.7 hours in these groups) but shorter (22.4 hours) in the young males. The mean maximum plasma sertraline concentration (Cmax) and the mean steady-state area under the plasma concentration-time curve from time zero to 24 hours postdose (AUC24) were also similar between the young females, elderly males and elderly females, but were approximately 25% lower in the young males. The time to Cmax was unaffected by age or gender and ranged from 6.4 to 6.9 hours.
N-Demethylsertraline is the principal metabolite of sertraline and does not contribute significantly to its serotonergic actions. The mean values for N-demethylsertraline trough plasma concentrations, AUC24 and Cmax were comparable in elderly males and females and young females but lower in young males. The ratios of mean AUC24 and Cmax for N-demethylsertraline to the AUC24 and Cmax for sertraline were similar between the 4 groups.
Adis International Limited Sertraline Young Male Clin Psychiatry Young Female
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
Blazer DG, Bachar JR, Manton KB. Suicide in late life: review and commentary. J Am Geriatr Soc 1986; 34: 519–25PubMedGoogle Scholar
Rudorfer MV, Potter WZ. Antidepressants: a comparative review of the clinical pharmacology and therapeutic use of the ‘newer’ versus the ‘older’ drugs. Drugs 1989; 37: 713–38PubMedCrossRefGoogle Scholar
Koe BK, Weissman A, Welch WM, et al. Sertraline, a new selective inhibitor of serotonin uptake. Psychopharmacol Bull 1983; 19: 687–91Google Scholar
Heym J, Koe BK. Pharmacology of sertraline: a review. J Clin Psychiatry 1988; 49 Suppl. 8: 40–5PubMedGoogle Scholar
Aberg-Wistedt A. The antidepressant effects of 5-HT uptake inhibitors. Br J Psychiatry 1989; 155 Suppl. 8: 32–40Google Scholar
Cohn CK, Shrivastava R, Mendels J, et al. Double-blind, multicentre comparison of sertraline and amitriptyline in elderly depressed patients. J Clin Psychiatry 1990; 51 Suppl. B: 28–33PubMedGoogle Scholar
Doogan DP, Caillard V. Sertraline: a new antidepressant. J Clin Psychiatry 1988; 49 Suppl. 8: 46–51PubMedGoogle Scholar
Preskorn SH. Recent pharmacologic advances in antidepressant therapy for the elderly. Am J Med 1993; 94(5A): 2–12SGoogle Scholar
Guy S, Silke B. The electrocardiogram as a tool for therapeutic monitoring: a critical analysis. J Clin Psychiatry 1990; 51 Suppl. B: 37–9PubMedGoogle Scholar
Hindmarch I, Shillingford J, Shillingford C. The effects of sertraline on psychomotor performance in elderly volunteers. J Clin Psychiatry 1990; 51 Suppl. B: 34–6PubMedGoogle Scholar
Jenkyn LR, Coffey DJ, Coffey AK, et al. Effects of antidepressants on cognitive and motor functions in the elderly. Presented as a scientific exhibit at the 49th Annual Scientific Meeting of the American Geriatric Society; November 14–18, Washington, DC: 1992Google Scholar
Tremaine LM, Joerg EA. Automated gas chromatographic-electron-capture assay for the selective serotonin uptake blocker sertraline. J Chromatogr 1989; 496(2): 423–9PubMedGoogle Scholar
Schmucker DL. Aging and drug disposition: an update. Pharmacol Rev 1985; 37: 133–48PubMedGoogle Scholar
Furlanut M, Benetello P. The pharmacokinetics of tricyclic antidepressant drugs in the elderly. Pharmacol Res 1990; 22: 15–25PubMedCrossRefGoogle Scholar
von Moltke LL, Greenblatt DJ, Shader RI. Clinical pharmacokinetics of antidepressants in the elderly. Clin Pharmacokinet 1993; 24: 141–60CrossRefGoogle Scholar
Greenblatt DJ, Harmatz JS, Shader RI. Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Part I. Clin Pharmacokinet 1991; 21: 165–77PubMedCrossRefGoogle Scholar
Greenblatt DJ, Harmatz JS, Shader RI. Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Part II. Clin Pharmacokinet 1991; 21: 262–73PubMedCrossRefGoogle Scholar
Gerson SC, Plotkin DA, Jarvik LF. Antidepressant drug studies, 1964 to 1986: empirical evidence for aging patients. J Clin Psychopharmacol 1988; 8: 311–22PubMedCrossRefGoogle Scholar
Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995; 50: 222–39PubMedCrossRefGoogle Scholar
Hunt CM, Westerkam WR, Stave GM. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 1992; 44: 275–83PubMedCrossRefGoogle Scholar
George J, Byth K, Farrell GC. Age but not gender selectively affects expression of individual cytochrome P450 proteins in human liver. Biochem Pharmacol 1995; 50: 727–30PubMedCrossRefGoogle Scholar
Wrightson SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992; 22: 1–21CrossRefGoogle Scholar
Sprouse J, Reynolds L, Heym J. Electrophysiological evidence that desmethylsertraline is inactive at blocking central 5-HT uptake in vivo. Neuropsychopharmacology 1994; 10 Suppl. 35: 235SGoogle Scholar
Depression in women. ACOG technical bulletin number 182 -July 1993. Int J Gynaecol Obstet 1993; 43(2): 203–11CrossRefGoogle Scholar
Weissman MM, Klerman GL. Sex differences and the epidemiology of depression. Arch Gen Psychiatry 1977; 34: 98–111PubMedCrossRefGoogle Scholar